BackgroundRamucirumab　(IMC-1121B)　is　a　fully　human　immunoglobulin　G1　monoclonal　antibody,　approved　by　the　US　Food　and　Drug　Administration　(FDA)　for　treating　various　cancers,　including　gastric,　colorectal,　liver,　and　non-small　cell　lung　cancer.　This　study　aimed　to　investigate　the　adverse　events　(AEs)　associated　with　ramucirumab　by　utilizing　data　mining　techniques　on　the　FDA　Adverse　Event　Reporting　System　(FAERS).MethodsWe　collected　ramucirumab-related　data　from　the　FAERS　database,　spanning　from　January　2014　to　June　2023.　Our　analysis　incorporated　both　Frequentist　and　Bayesian　methodologies　in　disproportionality　analysis　to　determine　the　relationship　between　the　drug　and　specific　AEs.ResultsAmong　the　14,605,547　reports　in　FAERS　database,　12,692,407　were　identified　as　primary　suspected　AEs　related　to　ramucirumab.　These　AEs　involved　26　different　organ　systems,　with　24　significant　disproportionality　Preferred　Terms　(PTs)　identified　across　four　algorithms.　Notably,　unexpected　significant　AEs,　such　as　peripheral　neuropathy,　hemolytic　uremic　syndrome,　rectal　stenosis,　anaphylactic　shock,　bladder　tamponade,　hydronephrosis,　and　spontaneous　pneumothorax,　were　also　observed.ConclusionThis　study　makes　a　significant　contribution　to　the　field　by　emphasizing　the　importance　of　long-term　monitoring　of　approved　agents　to　further　expand　on　potential　adverse　events　and　to　distinguish　between　events　that　are　disease-related　versus　those　more　directly　related　to　the　particular　treatment.